Mumbai, India,: Pharma major Lupin Limited (Lupin) today announced the extension of the ‘Jan Kovid’ Helpline (1800-572-6130) for the residents of Bhopal and Indore.
Seeking medical help during the lockdown poses a great challenge. This initiative facilitates medical outreach to citizens to resolve queries about COVID-19, its symptoms, details about nearest testing centers or government hospitals, and help for those suffering from stress, anxiety or respiratory issues. Backed by a team of general physicians, respiratory physicians and psychiatrists from these two cities, the helpline number will offer free consultation and respond to all queries related to COVID-19. The service is available in Hindi and English, and will be operational all days from 8 am – 8 pm.
Commenting on the initiative, Mr. Nilesh Gupta, Managing Director, Lupin said, “Our experience of the Mumbai Helpline was encouraging enough to consider extending it to Bhopal and Indore where we have major presence with our manufacturing facilities. In the current scenario of movement restrictions, most people cannot access medical advice or even clarify doubts pertaining to their health or that of their family. This only adds to their stress. We are happy to support the government authorities who are leading the fight against COVID-19 by launching this helpline for the citizens of Bhopal and Indore. The Jan Kovid helpline will offer advice for respiratory and mental symptoms. We urge people to use this facility to reach out to medical experts for consultations and seek their advice without stepping out of their homes.”
The toll-free helpline number 1800-572-6130 will be available from 8 am to 8 pm every day. A call back system is available next morning for calls received after hours to ensure all queries are addressed.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on
For further information or queries please contact –
Head – Investor Relations/Corporate M&A
General Manager – Corporate Communications